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Background: It has been suggested that transcriptional upregulation of cerebral artery contractile endothelin (ETB)
and 5-hydroxytryptamine (5-HT1B) receptors play an important role in the development of late cerebral ischemia
and increased vasoconstriction after subarachnoid hemorrhage (SAH). We tested the hypothesis that inhibition of
calcium calmodulin-dependent protein kinase II (CaMKII) may reduce cerebral vasoconstriction mediated by
endothelin and serotonin receptors and improve neurological outcome after experimental SAH.
Methods: SAH was induced in adult rats by injection of 250 μL autologous blood into the basal cisterns. The
CaMKII activity in cerebral vessels was studied by Western blot and immunohistochemistry. The vasomotor
responses of middle cerebral and basilar arteries were measured in a sensitive myograph system. The functional
outcome was examined by the rotating pole test 2 and 3 days after SAH.
Results: SAH induced a rapid early increase in phosphorylated CaMKII protein at 1 h that was attenuated by
cisternal administration of the CaMKII inhibitor KN93 (0.501 μg/kg) 45 min prior and immediately after SAH as
evaluated by Western blot. Application of KN93 at 1 h and every 12 h post-SAH significantly reduced vascular
CaMKII immunoreactivity at 72 h. In addition, contractile responses of cerebral arteries to endothelin-1 (ET-1) and
5-hydroxycarboxamide (5-CT) were increased at this time-point. KN93 treatment significantly attenuated the
contraction induced by ET-1 and 5-CT. Importantly, treatment with the CaMKII inhibitor prevented SAH-induced
deficits in neurological function, as evaluated by the rotating pole test, and similar sensorimotor scores were seen
in sham-operated animals.
Conclusions: The present study has shown that SAH is associated with increased contractile responses to ET-1
and 5-CT in cerebral arteries and enhanced early activation of CaMKII. Treatment with the CaMKII inhibitor KN93
attenuated the contractile responses and prevented impaired sensorimotor function after SAH.
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Subarachnoid hemorrhage (SAH) is associated with high
initial mortality (15%) and after several days the develop-
ment of delayed cerebral ischemia (DCI) and cerebral
vasospasm (CVS) causes further considerable morbidity
and mortality [1]. The pathophysiological mechanisms
responsible for DCI and CVS are still elusive, although a
number of associated factors have been revealed such as
enhanced levels of ions or free radicals [2,3], upregu-
lation of contractile endothelin receptors [4], reduced
levels of endothelial relaxant factors [5], elevation of
circulatory and/or local messenger molecules such as
endothelin-1 (ET-1) and 5-hydroxytryptamine (5-HT)
[6], and imbalance between vasoconstrictors and vaso-
dilators [1]. Hence, the mechanisms behind DCI after
SAH are likely complex and multifactorial [7].
ET-1 and 5-HT are potent cerebral vasoconstrictors
which mediate strong vasomotor responses through their
respective receptors; endothelin A (ETA), endothelin B
(ETB), 5-HT1B, and 5-HT2A receptors in rat cerebral ar-
teries [8]. It has been demonstrated that experimental
SAH induces upregulation of contractile ETB and 5-HT1B
receptors in the smooth muscle cells of cerebral arteries
[9]. The phenomenon of enhanced receptor expression is
thus not limited to only some receptor subtypes but also
associated with cerebrovascular inflammation [10]. Thus,
the responses to SAH are complex and, therefore, stu-
dies designed to test a single specific target of vaso-
constrictor receptor subtypes have been unsuccessful in
improving outcome after SAH [11]. Most recently, the
CONSCIOUSS trials using the ETA receptor antagonist
clazosentan failed to improve clinical outcome after SAH
and thereby brought an end to the long-standing hope of
helping SAH patients by direct targeting of endothelin re-
ceptors [12]. Novel approaches to the treatment of DCI
are therefore urgently needed.
The MEK/ERK1/2 protein kinase pathway has been ob-
served to play a central role in the upregulation of cere-
brovascular vasoconstrictor receptors and inflammation
pathways and is associated with DCI after SAH [13]. We
have found that cerebral arteries undergo vascular phe-
notypic changes after SAH and ischemic stroke [7]. In a
previous study, we have developed a method, using organ
culture, by which cerebrovascular receptor upregulation
can be examined in vitro [14-17]. By using this in vitro
model, it was observed that calcium calmodulin-dependent
protein kinase (CaMK) II is associated with upregula-
tion of contractile ETB receptors, activation of inflamma-
tion pathways, and the TNFα receptor 1 [10]. In addition,
we reported that the CaMKII and MEK1/2 pathways may
interact or cross-talk in this process [10].
CaMKII is a multifunctional serine/threonine kinase
with various cellular functions, including gene expres-
sion, cell cycle control, and hormone production [18]. Ithas been shown that CaMKII has a significant effect on
downstream regulatory element antagonist modulator
(DREAM), which is a Ca2+-regulated transcription re-
pressor. Interestingly, it has been shown that CaMKII
inhibitors reduce upregulation of contractile ETB recep-
tors [19] and has a neuroprotective effect after experi-
mental ischemic stroke [20]. CaMKII is important for
regulation of intracellular Ca2+ homeostasis in the over-
all regulation of vascular smooth muscle cell contraction
[21]; however, we postulate that, in addition, CaMKII may
participate in expression of vascular endothelin receptors
and cerebrovascular inflammation responses.
The aim of the present study was to address the hy-
pothesis that inhibition of CaMKII with KN93 in vivo
prevents CaMKII activation and reduces DREAM expres-
sion in cerebral arteries after SAH, reduces vasoconstric-
tion mediated by endothelin and serotonin receptors, and
improves functional outcome after SAH.
Materials and methods
Rat SAH model
All procedures were performed strictly within national
laws and guidelines and were approved by the Danish
Animal Experimentation Inspectorate (license no. 2011/
561-2025).
SAH was induced as previously described [22]. Briefly,
male Sprague-Dawley rats, weighing 320 to 340 g body
weight, were anesthetized using 4% isoflurane (Abbott
Laboratories, Illinois USA) in atmospheric air/O2 (70:30).
The rats were orally intubated and kept on artificial venti-
lation with inhalation of 1 to 2% isoflurane in N2O/O2
(70:30) during the surgery. Respiration was monitored
by regular withdrawing of blood samples to a blood gas
analyzer (Radiometer, Copenhagen, Denmark). One cath-
eter was placed in the tail artery to measure blood pres-
sure and another in the cisterna magna to measure the
intracranial pressure (ICP). On the right side of the skull,
4 mm anterior from bregma and 3 mm to the midline, a
hole was drilled through the bone to the dura mater with-
out perforation and a laser-Doppler probe was placed to
measure cortical cerebral blood flow.
A 27G blunt cannula with a side hole facing right was
placed stereotactically 6.5 mm anterior to the bregma in
the midline at an angle of 30° to the vertical plane pla-
cing the tip of the needle just in front of the chiasma
opticum. The rat was placed on a heating pad connec-
ted with a rectal probe to keep the core temperature at
37.5 ± 0.5°C. After 30 minutes of equilibration, during
which the level of anesthesia was adjusted to obtain
a mean arterial blood pressure of 80 to100 mmHg,
250 μL of blood was withdrawn from the tail catheter
and injected manually into the pre-chiasmatic cistern at
a pressure equal to the mean arterial blood pressure.
Subsequently, rats were maintained under anesthesia
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cover. The ICP catheter was cut and closed with a re-
movable plug (later to be used for administration of
treatment) 2 cm from the tip, the tail catheter, the nee-
dle, and the laser-Doppler probe was removed and inci-
sions closed. The rat was revitalized and extubated. At
the end of the surgery and every 24 h until termination,
the rat received a subcutaneous injection of Carprofen
(4 mg/kg, Pfizer, Denmark) and 15 mL of isotonic sa-
line for hydration. Sham-operated rats went through
the same procedure, with the exception that no blood
was injected intracisternally. In total, we included 70
animals in this study. The detailed number of animals
is presented in the Results section. The experimental
design is presented in Figure 1.KN93 and vehicle treatment groups
Rats in placebo and KN93 treatment groups went through
the same surgical procedure as the above described SAH
animals. Animals in the KN93 group were treated with
50 μL of a 10−5 M solution of KN93 (Cayman Chemicals,
USA), yielding a final dose of 0.501 μg/kg body weight for
a 330 g rat, diluted in isotonic saline +0.01% DMSO every
12 h with the first dose given 1 h post-SAH. The KN93
concentration was chosen based on earlier in vitro studies
[19]. KN93 was delivered intracisternally through the ICP
catheter with the tip placed in the cisterna magna. Ani-
mals in the placebo group were treated at the same time
points with a corresponding volume of isotonic saline
+0.01% DMSO via the same administration route.
For investigations of the CaMKII phosphorylation in
cerebral arteries at 1 h after SAH, rats were treated with
KN93 (dose as above) or placebo (as above) 45 minutes
before induction of SAH and again immediately after in-
duction of SAH. For investigations of CaMKII phos-
phorylation in cerebral arteries at 6 and 24 h after SAH,
rats were treated with KN93 (dose as above) or placebo
(as above) at 1 h post-SAH and repeated at 12 h post-
SAH (for rats terminated at 24 h). An overview of theFigure 1 Experimental design. *Animals terminated at 1 h for
evaluation of phosphorylated CaMKII with Western blot were treated
with KN93 or placebo 45 min prior to and immediately after SAH.treatment regimen and experimental groups are presen-
ted in Figure 1.
Rotating pole test
Gross sensorimotor function (integration and coordin-
ation of movements as well as balance) was evaluated by
the ability of the rats to traverse a rotating pole on days
2 and 3 after SAH [23]. In one end of the pole (which
was 45 mm in diameter and 150 cm in length) a cage
with an entrance hole facing the pole was placed and the
floor of the cage was covered with bedding material
from the home cage of the rat being tested, thus serving
as a positive reinforcement for the rat to traverse the
pole when placed at the end opposite to the cage. The
performance of the rats was scored according to the fol-
lowing definitions: score 1) the animal is unable to bal-
ance on the pole and falls off immediately; score 2) the
animal balances on the pole but has severe difficulties
crossing the pole and moves less than 30 cm; score 3) the
animal embraces the pole with the paws and does not
reach the end of the pole, but manages to move more than
30 cm; score 4) the animal traverses the pole, but em-
braces the pole with the paws and/or jumps with the hind
legs; score 5) the animal traverses the pole with normal
posture but with more than 3 to 4 foot slips; score 6) the
animal traverses the pole perfectly with less than 3 to 4
foot slips. Each animal was tested on 0, 3, and 10 rotations
per minute (rpm).
Harvest of cerebral arteries
At 1, 6, or 24 h (for Western blot analysis of CaMKII
phosphorylation) or at 72 h (for contractility measurements
and immunohistochemistry of CaMKII and DREAM
expression) after SAH or sham operation, rats were de-
capitated. The brains were quickly removed and chilled
in cold bicarbonate buffer solution. The middle cerebral
artery (MCA) and the basilar artery (BA) were carefully
dissected from the brain.
Western blot
The BA and both MCAs were isolated, cleared of blood
and connective tissue, and snap frozen as one pooled
sample of all three vessel segments from each rat. Each
sample of frozen arteries were lysed in 70 μL boiling LDS
sample buffer (Expedeon, Cambridgeshire, UK) containing
50 mM DTT, sonicated for 2 min and cleared by cen-
trifugation at 15,000 at 4°C for 30 minutes. Then, 20 μL
of each sample was separated by 4 to 20% SDS-PAGE
(RunBlue, Expedeon, San Diego, CA, USA) and trans-
ferred to a PVDF membrane. Membranes were blocked
in PBS with 0.1% Tween-20 and 5% bovine serum albu-
min (BSA) (Sigma-Aldrich, St Louis, MO, USA) for 1 h at
room temperature and then incubated overnight at 4°C in
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phospho-CaMKII (Thr286; Cell Signaling Technology,
Beverly, MA, USA) diluted 1:1,000, followed by incu-
bation with ECL™ horseradish peroxidase-conjugated
donkey anti-rabbit IgG antibody (GE Healthcare, Uppsala,
Sweden) for 1 h at room temperature. Labelled proteins
were developed using Lumigen TMA-6 chemilumines-
cence solutions (GE Healthcare). Subsequently, the mem-
branes were incubated in stripping buffer, extensively
washed in PBS +0.1% Tween-20, and then re-probed with
the primary antibody mouse anti-rat CaMKII (Abcam,
Cambridge, UK) diluted 1:200, at 4°C overnight in blocking
buffer followed by incubation with horseradish peroxidase-
conjugated goat anti-mouse IgG antibody (Pierce/Thermo
Scientific, Rockford, IL, USA) 1:5,000 for 1 h at room
temperature and development of labelled proteins. La-
belling chemiluminescence intensities were quantified
using the software Image Gauge V4.0 (Fujifilm, Tokyo,
Japan). The quantitative data have been presented before
(see below). Finally, as a loading control, membranes were
washed and re-probed with mouse anti-actin antibodies
followed by anti-mouse secondary antibodies as described
above.
In vitro pharmacology
For measurements of contractile responses of cerebral
arteries, a wire myograph (Danish Myograph Technology
A/S, Aarhus, Denmark) was used to record the isometric
tension in segments of isolated cerebral arteries [24,25].
Briefly, 1 mm long vessel segments were mounted on
two 40 μm diameter stainless steel wires in a set-up pre-
viously described [4]. The segments were immersed in a
temperature-controlled buffer solution (37°C) of the fol-
lowing composition (mmol/L): NaCl 119, NaHCO3 15,
KCl 4.6, MgCl2 1.2, NaH2PO4 1.2, CaCl2 1.5, and glu-
cose 5.5. The buffer was continuously aerated with 5%
CO2 resulting in a pH of 7.4. The vessel segments were
stretched to an initial pretension of 1 to 2 mN/mm and
allowed to equilibrate at this tension for 45 min. The
vessels were then exposed to a solution of 63.5 mM K+
obtained by partial substitution of NaCl for KCl in
the above described isotonic solution. The K+-evoked
contractile responses were used as reference values for
normalization of agonist-induced responses and to evalu-
ate the contractile capacity of the vessels [24]. Only BAs
with K+-induced responses over 2 mN and MCAs with
K+-induced responses over 0.7 mN were included in
the study. The presence of functional endothelium in
the vessel segments was assessed by means of pre-
contraction with 5-HT followed by relaxation with carba-
chol as previously described [9]. Concentration-response
curves were obtained by cumulative application of 5-
carboxamidotryptamine (5-CT) (Sigma-Aldrich) in the con-
centration range 10−14 to 3 × 10−7 M and ET-1 (AnaSpec,San Jose, CA, USA) in the concentration range 10−14
to 3 × 10−7 M.
Immunohistochemistry
Vessel segments were embedded in Tissue TEK (Gibco,
Invitrogen A/S, Taastrup, Denmark), frozen at −80°C,
and cryosectioned (10 μm, Cryo-star HM 560 M Thermo
Scientific, Microm, Germany). The sections were fixed for
10 min in −20°C acetone and rehydrated by 3 × 5 min
phosphate buffered saline (PBS, pH 7.2) containing 0.25%
Triton X-100 (PBST). The sections were incubated over-
night at 4°C with primary antibodies, anti-DREAM (1:250,
FL-214, sc-9142 Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and anti-CaMKII (1:100, ab-52476, Abcam)
diluted in PBST containing 1% BSA. After incubation,
sections were washed in PBST for 2 × 15 min and incu-
bated for 1 h at room temperature with FITC-conjugated
secondary antibody (1:100 Cayman Chemicals, Ann Arbor,
MI, USA) diluted in PBST containing 1% BSA. The sec-
tions were then washed in PBST for 2 × 15 min and moun-
ted with anti-fading mounting medium (DAPI-containing
Vectashield; Vector Laboratories Inc., Burlingame, CA,
USA). The same experimental procedure was used for
negative controls, where primary antibodies were omitted.
This resulted in no immunoreactivity except for auto-
fluorescence in the internal elastic lamina. Immunoreac-
tivity was visualized at the appropriate wavelength with an
epifluorescence microscope (Nikon 80i; Tokyo, Japan) and
photographed with an attached Nikon DS-2Mv camera.
The fluorescence intensity was measured with the Image J
software (http://rsb.info.nih.gov/ij/) in a blinded fashion
by a second unbiased person. Each treatment group con-
tained 5 to 7 rats, and 4 to 6 sections were evaluated for
each rat. The fluorescence intensity was measured in four
standardized areas (two, four, eight, and ten o’clock) in
each section. The mean intensity per measured area was
used as the fluorescence measurement. Results are shown
as mean ± standard error of the mean and n refers to the
number of vessels in each group for each antibody.
Statistics
Data are presented as the mean ± SEM. Statistical ana-
lyses were performed using one-way ANOVA for the im-
munohistochemistry quantifications, two-way ANOVA
with agonist concentration and experimental group as
the two independent variables for the contractility curves,
and non-parametric Kruskal-Wallis test for the rotating
pole test. P <0.05 was considered significant.
Results
Subarachnoid hemorrhage (SAH) model
In all operated rats, mean arterial blood pressure, partial
pCO2, partial pO2, pH, and body temperature were within
normal physiological ranges during the operation. There
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among the groups. As a result of injecting blood, the cor-
tical blood flow dropped over the right hemisphere to
10.3 ± 13% of resting flow and the ICP increased from
4.2 ± 5 mmHg to 128 ± 41 mmHg. The blood flow and
ICP returned to basal values within 1 h after injection
(for typical responses see [26]). There was no difference
in ICP rise and cortical blood flow drop between treat-
ment groups. The treatment with KN93 was well tolerated
by the animals throughout the 72 h post-SAH period and
did not induce any acute changes in the above parameters.
There were no significant differences in the mortality rates
between treatment groups.
CaMKII phosphorylation in cerebral arteries
To assess whether CaMKII is activated in cerebral arter-
ies after SAH, and to investigate the time-course of this
activation, we performed Western blots of cerebral arter-
ies from rats terminated at 1, 6, and 24 h after SAH or
sham-operation with antibodies against CaMKII phos-
phorylated at Thr286 (indicating activation of CaMKII).
Moreover, to test the effect of the CaMKII inhibitor
KN93 on SAH-induced CaMKII activation (pCaMKII/
total CaMKII; % of sham), we included a group of SAH
rats treated with KN93 at each time point. As shown in
Figure 2, a clear activation of CaMKII in cerebral arte-
ries at 1 h post-SAH was observed (180 ± 29%; n = 4)
and this SAH-induced CaMKII activation was prevented
by treatment with KN93 45 min prior to and immediately
after SAH (49 ± 11%; P <0.05). However, the SAH-induced
CaMKII activation declined to sham-operated levels at
6 and 24 h post-SAH (at these time points there were
no differences between the groups, data not shown) [27].
Thus, CaMKII activation appears to be an early, transientFigure 2 Western blot of early CaMKII phosphorylation in
cerebral arteries after SAH. Representative blots of phosphorylated
CaMKII and total CaMKII levels in cerebral arteries from rats terminated
1 h after SAH (given placebo or KN93) or sham-operation. KN93 or
placebo were given 45 min prior to and immediately after SAH.
Number of animals in each group, n = 4.event in cerebral arteries after SAH. In support, elevation
of phosphorylated CaMKII at 0.5 to 1 h after SAH induc-
tion was recently verified in a phosphoproteomic study
[27]. We next continued to examine and understand the
role of early CaMKII activation in arterial phenotypic
changes and functional outcome after SAH.
Protein levels of CaMKII and DREAM in cerebral arteries
Immunohistochemistry was used to investigate whether
SAH affects CaMKII expression in cerebral arteries. As
shown in Figure 3A,B, CaMKII protein expression in-
creased in cerebral vascular smooth muscle cells after
SAH compared to sham (P <0.05). Interestingly, KN93
significantly decreased the CaMKII immunoreactivity
compared to SAH (P <0.01, Figure 3A,B). We have pre-
viously shown that organ culture of cerebral arteries in-
duces CaMKII activation [10,19], which in turn induces
increased expression of the DREAM transcription repres-
sor. Here, we investigated if SAH-induced CaMKII activa-
tion also affects downstream DREAM protein expression.
A significant increase in the DREAM immunoreactiv-
ity was observed after SAH compared to sham (P <0.05,
Figure 3C,D). Treatment with KN93 prevented the increase
in DREAM protein expression compared to the untrea-
ted SAH group or SAH treated with placebo (P <0.01,
Figure 3C,D).
Contractile responses of cerebral arteries
Potassium (63.5 mM) induced a potent vasoconstriction
in all vessels and was used as an internal control set to
100%. There was no difference in the potassium-induced
responses between the groups studied. Contractile re-
sponses to cumulative administration of ET-1 (10−14 to
10−7 M) are shown in Figure 4. In cerebral arteries from
sham-operated rats, ET-1 induced sigmoidal concentration-
response curves in both MCA and BA. SAH (untreated
or placebo) resulted in leftward shifts, and a change from
sigmoidal to biphasic concentration-response curves. This
is in accordance with our earlier studies, which demon-
strated that the first phase of the ET-1 concentration-
response curves represents contraction mediated by
contractile ETB receptors upregulated in the smooth
muscle cells after SAH, whereas the second phase of
the curve represents vasoconstriction mediated by ETA
receptors [9]. The change into a biphasic curve together
with the increased Emax values after SAH suggests upre-
gulation of both ETA and ETB receptors after SAH. The
detailed pharmacological characterizations have been pub-
lished before [4,9,28]. Treatment with KN93 totally abol-
ished the elevation of the first phase but not the second
phase, thus yielding ET-1 concentration-response curves
similar to the vascular contractile response seen in arteries
from sham operated animals. This indicates that KN93
prevents the expression of ETB receptors after SAH.
Figure 3 Immunohistochemistry evaluation of the CaMKII and DREAM expression in cerebral arteries. (A, B) Markedly increased CaMKII
protein expression at 72 h post-SAH. KN93 decreased the CaMKII expression significantly. (C, D) Increased DREAM protein expression in SAH and
SAH + Placebo groups. Administration of KN93 decreased the DREAM immunoreactivity significantly. The protein expression of CaMKII and DREAM
in the different groups was compared to SAH as control. No staining, except for autofluorescence in the internal elastic lamina, was observed in
the negative controls were primary antibodies were omitted (data not shown). *P <0.05 and **P <0.01 vs. SAH. Values are presented as mean ± SEM.
Number of animals in each group, n = 5–7.
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5-CT (10−14 to 3 × 10−7 M) are shown in Figure 5. 5-CT
yielded biphasic concentration-response curves in both
MCA and BA, mediated by the presence of 5-HT1B (first
phase of the concentration-response curve) and 5-HT2AFigure 4 Cerebrovascular contractile responses to ET-1 at 72 h post-S
application of ET-1 to (A) MCA and (B) basilar arteries. In both arteries, the firs
contraction via ETB receptors and the second phase contraction mediated by
detail [4,9,28]. Values are expressed as percentage of the K+-induced contracti
each group, n = 6–8.(second phase) receptors as previously characterized in
detail [29]. Contraction induced by 5-CT in cerebral
arteries from SAH rats (untreated or placebo) showed
leftward shifts and increased Emax values compared to
sham, indicating upregulation of cerebrovascular 5-HTAH. Concentration-response curves were elicited by the cumulative
t phase of the concentration-response curve represents ET-1-induced
ETA receptors. Previous studies have characterized these responses in
on and are presented as mean ± SEM. ***P <0.001. Number of animals in
Figure 5 Cerebrovascular contractile responses to 5-CT at 72 h post-SAH. Concentration-response curves were elicited by the cumulative
application of 5-CT to (A) MCA and (B) basilar arteries. The 5-CT induced contractile responses show two phases; the first part represents elevation
in the 5-HT1B receptor expression and the second part shows unaltered 5-HT2A receptor function in MCA and BA after SAH. The detailed
pharmacological characterizations have been previously published [4,9,28,29]. Values are expressed as percentage of the K+-induced contraction
and are presented as mean ± SEM. **P <0.01 and ***P <0.001. Number of animals in each group, n = 6–8.
Edvinsson et al. Journal of Neuroinflammation 2014, 11:207 Page 7 of 9
http://www.jneuroinflammation.com/content/11/1/207receptors after SAH. Treatment with KN93 abolished
the elevation of the first phase but not the second
phase, yielding 5-CT concentration-response curves as
seen in arteries from sham-operated animals. This indi-
cates that KN93 prevents the enhanced expression of
5-HT1B receptors after SAH.
Sensorimotor function
The conclusion from the clazosentan treatment trial pro-
gram was that CVS was not the key endpoint but the out-
come of SAH, indicating the importance of DCI as the
best endpoint in evaluation of trials. Therefore, we used
the integration and coordination of movements as evalu-
ated by the rotating pole test [23]. When tested 2 days
after SAH or sham-operation, sham rats obtained an ave-
rage score of 5.2 ± 0.2 in the no rotation test, whereas
animals in SAH and SAH with placebo groups obtainedFigure 6 Sensorimotor function 2 days after SAH. Animals were tested
and (C) 10 rpm. *P <0.05 and **P <0.01 compared to sham. Animals were
with less than 3 to 4 foot slips. Values are presented as mean ± SEM. Numbsignificantly lower scores (3.5 ± 0.3 and 3.2 ± 0.4, respec-
tively, P <0.01) in the no rotation test (Figure 6A). KN93
treatment prevented the worsened sensorimotor func-
tion after SAH and treated rats had an average score of
4.3 ± 0.5, which was not significantly different from the
sham group. Performing the test with rotation at 3 rpm
and 10 rpm decreased the performance of the rats in all
groups (Figure 6B,C). However, untreated and placebo-
treated SAH rats obtained lower scores than sham-
operated rats and KN93-treated SAH rats. These data
suggest improved gross sensorimotor function after treat-
ment with the CaMKII inhibitor in SAH. Treatment of
sham rats with KN93 did not show modified responses as
compared to sham rats (data not shown). At 3 days after
SAH or sham-operation, the results of the rotating pole
test were similar to results obtained at day 2 but less
marked between groups (data not shown).on the rotating pole at (A) 0 rotations per minute (rpm), (B) 3 rpm,
given a maximum score of 6 if they could traverse the pole perfectly
er of animals in each group, n = 6–13.
Edvinsson et al. Journal of Neuroinflammation 2014, 11:207 Page 8 of 9
http://www.jneuroinflammation.com/content/11/1/207Discussion
The etiology of CVS and DCI after SAH remains an un-
resolved issue. Involvement of mitogen activated protein
kinases (MAPK) and, in particular, the MEK/ERK1/2
pathway has been demonstrated, and early inhibition
of these protein kinases may significantly alleviate DCI
and improve outcome after experimental SAH in rats
[4,28]. This was strongly supported by a study of signal-
transduction mechanisms activated after SAH in a phos-
phoproteomic study with quantitative mass spectrometry
[27]. The CaMKII and MEK/ERK1/2 pathways were acti-
vated at 0.5 and 1 h after the SAH and seemed to correl-
ate in a time-dependent manner. Recently, we reported
evidence for a cross-talk between these two kinase sys-
tems using an organ culture method [10]. Because of
this work, designed to understand the details of intra-
cellular mediators activated after SAH, we asked the
current question of whether CaMKII has a role in in-
duction of vasoconstrictor receptor upregulation and if
its inhibition may improve outcome after SAH. Organ
culture has been used as a model that has allowed for a
detailed molecular mechanistic analysis aimed at evalu-
ating the role of different kinases, including MAPK and
CaMKII, on the transcriptional upregulation of endothelin
and 5-HT receptors [30]. These studies have shown that
CaMKII is activated in rat cerebral arteries [19] after
organ culture and in vivo after different types of stroke
[27]. Here, we report that phosphorylated CaMKII is ele-
vated early after induction of SAH, at 1 h, but transiently.
In addition, the inhibition of CaMKII with KN93 has pre-
viously been demonstrated to decrease the mRNA level of
endothelin ETA and ETB receptors, and to reduce ET-1
and sarafotoxin 6c (ETB receptor-specific agonist)-induced
contractions [19].
The present study is thus the first to demonstrate the
in vivo effect of the CaMKII inhibitor KN93 in a well-
characterized rodent SAH model [28]. The in vivo re-
sults show that KN93 administration attenuated the
SAH-induced elevation of contractions induced by ET-1
(mediated by ETA and ETB receptors) in BA and MCA
arteries. In addition, KN93 treatment abolished the first
phase in the biphasic concentration-response curve in-
duced by 5-CT, indicating prevention of 5-HT1B recep-
tor upregulation after SAH. We observed that KN93
successfully attenuated contractions induced by ET-1
and 5-CT. In support, it has been shown that the circu-
latory levels of 5-HT and ET-1 increase after SAH [6].
Thus, the inhibitory effect of KN93 on contractions in-
duced by 5-CT and ET-1 suggests an important role of
CaMKII in mediating the elevated vascular contractions
after SAH.
It has also been shown that [Ca2+]i and CaMKII co-
operatively regulate the subcellular localization into the
nucleus and thereby promotes downstream DREAM-induced transcriptional repression [31]. The present re-
sults show, for the first time, that SAH induced increased
arterial DREAM expression, and this expression was sig-
nificantly attenuated following KN93 treatment. Taken to-
gether, the results support the involvement of CaMKII in
downstream regulation of DREAM at the transcriptional
level after experimental SAH.
Evaluation of the gross sensorimotor function after
SAH showed that KN93 had an effect on the neurological
outcome after SAH. Treatment with KN93 at 1 h and
every 12 h post-SAH prevented worsened neurological
function at 2 days (seen in SAH and SAH+ placebo ani-
mals) and similar test scores were achieved as in sham-
operated rats. Although KN93-treated rats tended to have
higher scores than SAH and SAH+ placebo, this diffe-
rence was not significantly different. The dose of KN93
(0.501 μg/kg) was based on a previous in vitro study using
the organ culture method. This concentration is low
compared to another study that administered a differ-
ent CaMKII inhibitor at 1 mg/kg intravenously for the
treatment of ischemic stroke in rats [20]. It may be in-
teresting to investigate higher concentrations and other
available CaMKII inhibitors to evaluate if they may have
stronger effects on the neurological outcome after SAH.Conclusions
The present study has revealed the involvement of CaMKII
in the events occurring after SAH. Increased vasocon-
striction to ET-1 and 5-CT was observed in cerebral ar-
teries, as well as elevation of vascular smooth muscle
CaMKII and DREAM protein expression. Treatment with
the CaMKII inhibitor KN93 significantly attenuated the
increase in contractile responses and in CaMKII and
DREAM protein levels and prevented sensorimotor de-
ficits after SAH.
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